Member Info for Basser1

January to March big updates perhaps. Don’ like your agenda here.

Stevej - the wording of the contract does not state a definite ending of the contract after 9 months. It states “The agreement may be terminated” ie the definition of “May” means “expressing a possibility”. This provides wriggle room for a further extension if Sareum is fully satisfied that good progress is being made on the agreed outcome. However, we should now at the least expect an RNS clearly outlying the progress that has been made.

This may be a once in a lifetime opportunity. All for 2.25p per share. What are the odds of success in Covid treatment? I would put it at 50/50 given the results of the Lupus tests. And then there is also a potential to treat wide range of inflammatory diseases and also Cancer. Surely worth at least a small punt! Important you do your own research and only invest what you can afford to lose.GLA

It is around 50-60% effective in treating seriously ill patients. If SDC1801 can match that think we we would be well on way for £1. If we can beat that - sorry I feel faint.

Merck will get 356 million dollars for 60000-100000 doses. The mind boggles.

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwi4zICzoOXtAhWPTxUIHQi-AgUQFjAAegQIBBAC&url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fmerck-announces-supply-agreement-with-u-s-government-for-initial-doses-of-investigational-biological-therapy-for-the-treatment-of-patients-with-severe-and-critical-covid-19%2F&usg=AOvVaw0wq1WCtSEUhsskht0zgsS2

Mafuta - Since the “ moving premises” announcement, trading volumes have remained high despite the lack of any further news. The market seems to see some significance in the relocation near to Gilead. Shouldn’t be too long now before we hear of details of structural arrangements for taking forward the SRA737 clinical trials in the USA. Think a bookie would only offer you 2-5 on that Gilead will be involved.

Think the smart money will pile in this afternoon. Too good an opportunity to miss. Let’s see

Num - I understand that there would be a three month process between filing for CTA and gaining approval for clinical trials. But these are not normal times and we expect the Government to push this treatment forward ASAP to treat COVID 19. Doesn’t that have an impact on your assumptions as you have not mentioned COVID 19?

A long shot but perhaps GSK have been in discussions with Sareum about some of the other less well known assets in the Pipeline and are prepared to risk what would be small money in pharma terms to buy one of them.

In my opinion a takeover of the Company in the range of 28p if agreed by the Shareholders would be a straightforward way to exit our investments. However, there is no doubt in my mind that the takeover , whilst maybe attractive would bear no resemblance to the ultimate value of SDC-01 ( COVID and auto immune) SDC1802 (Cancer) SRA737 and Aurora Flt. If Sareum are told to get on with getting SDC1801 ready for fast track to treat COVID and it shows that it works, that is going to release a massive revenue stream that could then be used to support the ongoing development of both SDC1801 and SDC1802 in inflammatory diseases and Cancer. We would also benefit greatly if SRA737 becomes a key component of the combination therapies that can treat a wide range of cancers. As for Aurora that would be another bonus if the Chinese Company take it to market outside of China. Lots of risk and time related but If you want a Celgene type result that would seem to me the way to go.
N

The Sierra RNS issued today informed the market that it was moving premises from Vancouver to San Francisco Bay on a 48 month lease arrangement. This move locates Sierra very close to Giliad premises (within walking distance). The announcement triggered heavy volume share trading - nearly 4 times the six month daily average. The announcement did not give a rationale for the move but could be seen as a strategic move to facilitate the roll out of SRA 737 in the USA - with the likelihood that Gilead will be a key partner in the next clinical trials. This to me all points to an announcement in New Year, hopefully in January confirming the partnership arrangement and the release of agreed contractual payments to CRI and Sareum. A number of scientific papers including the Lancet and CRI have suggested that the combination of immunotherapy treatments that include SRA 737 are the next step forward in the treatment of a wide range of Cancers.

Sorry meant Sierra leasing.

Regarding the form 8-K today it seems that Gilead have leased new premises. What may be significant is that the premises are only a short walk away from Gilead’s premises. Interesting to say the least.

4 Nest eggs that can all turn into Golden Eggs.

Lutonnews - enjoy! We all have our dreams. Cheers!

Thanks Num. I sent an E Mail to UKRI yesterday pointing out the link between the Sareum Grant and the latest scientific find on TYK2. Good to hear that UKRI will be on the ball with this.

Dec 2019. “The company continues to engage with potential partners with a view to securing commercial licenses”

Dec 2020. “The company continues to ACTIVELY engage with potential partners with a view to securing commercial licenses”.

Definition of ACTIVELY. “Something that is happening right now”.

So lots going on now behind the scene. Won’ t be too long to wait for a deal in my opinion. Good Luck all LTH

Workingpharma - think it was the lupus trial but Num will know for sure!

Thanks for pointing that out. It seems that they are in the next phase of their proposal, whatever that means. Still think the option for a fast track should be investigated by Sareum. The Awarding body can only say no.